Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Genes predict response of adult leukemia patients to chemotherapy

22.03.2004


Genes can indicate which adult leukemia patients will respond to therapy and what the duration of their remission will be, according to a new study published in the April 1, 2004, issue of Blood, the official journal of the American Society of Hematology.



Researchers from the Dana-Farber Cancer Institute in Boston, Mass., and the University "La Sapienza" in Rome studied 33 patients that had all been recently diagnosed with adult T-cell acute lymphocytic leukemia (T-ALL), a type of cancer in which the body makes too many T lymphocytes.

"The present study investigates, for the first time, the identification of gene expression profiles associated with both short-term and long-term outcome in adult patients with T-ALL. While approximately 70 percent of pediatric patients with T-ALL have excellent long-term response to intensive chemotherapy, adult patients have a much less favorable outcome. Previously, this poor prognosis of adult T-ALL patients had not been attributed to specific genetic signatures," according to Jerome Ritz, M.D., of the Dana-Farber Cancer Institute, co-senior author of the study. Robin Foa, M.D., from the University "La Sapienza," also served as senior author.


Using microarray technology, a technique that can evaluate the expression of thousands of genes at once, researchers were able to compare the gene expression profiles of the patients who responded to chemotherapy to those who did not. Through gene expression profiling – a determination of which genes in a cell or group of cells are active – the scientists identified a single gene, IL-8, that was highly expressed in T-ALL cells that were resistant to treatment. Researchers also discovered a set of 30 genes that were highly expressed in leukemic cells from patients who achieved complete remission.

A model based on the expression of three genes – AHNAK, TTK, and CD2 – was also found to be highly predictive of the duration of remission, correctly classifying 71 percent of outcomes. The model was later verified by T-ALL samples taken from a separate group of 18 patients. Two conventional measures for predicting a patient’s outcome – the white blood cell count and the degree of differentiation (a comparison of the similarity between cancerous cells and their normal counterparts) – were also examined and appeared to be less predictive than the three-gene expression model.

The results of the study may help doctors customize a T-ALL patient’s treatment plan based on the individual’s predicted response to therapy using these methods. Further exploration of these genes may also lead to new therapeutic targets for adult T-ALL.

According to Donald Miller, M.D., Ph.D., Professor in the Division of Hematology at the University of Louisville and Director of the James Graham Brown Cancer Center in Louisville, Ky., "This work represents one of the first applications of genomics to an important clinical problem. It provides strong evidence that genetic analysis will help us provide better care to patients with leukemia and other malignant diseases."



This work was supported by the National Institutes of Health grant CA66996, the Ted and Eileen Pasquarello Research Fund, the Associazione Italiana per la Ricerca sul Cancro, the Instituto Superiore di Sanita, the Ministero dell’Istruzione, dell’Universita e della Ricerca Scientifica (MIUR), the Progetto FIRB, and the Associazione per le Leucemie Acute dell’adulto "Cristina Bassi" e Fondazione Cassa di Risparmio di Genova e Imperia.

Aislinn Raedy | EurekAlert!
Further information:
http://www.hematology.org/
http://www.bloodjournal.org

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>